Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | PNP | P00491 | 3/20 | 0.58 |
| ▸ | MPO | P05164 | 2/20 | 0.44 |
| ▸ | TPO | P07202 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25834247 | 0.85 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL985624 | 0.80 | PNP (0.66) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3699117 | 0.79 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL5515323 | 0.78 | ADORA2A (0.71) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7466316 | 0.78 | ADORA2A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL30488609 | 0.77 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Enprofylline SCHEMBL156402 | 0.76 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Enprofylline SCHEMBL1817246 | 0.76 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL10980302 | 0.76 | ADORA2A (0.72) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8351662 | 0.75 | ADORA2A (0.67) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-06-17 | — | — | US | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | CD4, GZMB, CRBN | PDE4A 1419/4885PDE4B 806/4885PDE4C 1009/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | PDE4A 2567/4885PDE4B 1607/4885PDE4C 1904/4885 |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, GZMB, CRBN | PDE4A 1419/4885PDE4B 806/4885PDE4C 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.